MeMed

**Product and the concrete problem it solves.** MeMed attacks one of medicine's most expensive and consequential everyday decisions: when a patient presents with a fever or suspected acute infection, is it bacterial (antibiotics may help) or viral (antibiotics do nothing but drive resistance and side effects)? Conventional tools answer this badly. Culturing a pathogen is slow, often takes 24-72 hours, fails when the infection site is inaccessible or unknown, and misses the roughly large fraction of cases where no organism is ever isolated; single markers such as C-reactive protein or procalcitonin are only weakly discriminating; and syndromic PCR panels detect *carriage* of an organism without proving it is the cause of illness. The result is chronic over-prescription of antibiotics, a principal driver of antimicrobial resistance (AMR), alongside missed bacterial infections. MeMed's answer is to stop hunting the pathogen and instead **decode the host's immune response** — the pattern of proteins the body itself produces — into a single, actionable bacterial-versus-viral score. Its flagship **MeMed BV** delivers that score, and its companion **MeMed Key** is a compact bench-top immunoassay analyzer that runs the test from a small blood sample at the point of need in roughly 15 minutes, moving a formerly central-lab-grade measurement to the emergency department, urgent-care clinic, or bedside.

**Core technology and how it actually works.** MeMed BV measures and computationally integrates the circulating levels of three immune-system proteins — **TRAIL** (a viral-induced protein that rises in viral infection), **IP-10**, and **CRP** — and fuses them through a proprietary machine-learning algorithm into a 0-100 score reflecting the likelihood that the underlying infection is bacterial. No single one of these markers is sufficient; the differentiation comes from the pattern and the learned weighting across them, which is where MeMed's decade-plus of immunology and computational-biology work is concentrated. The scientific bet — that the immune system is a faster, more universal "reporter" of infection type than the pathogen itself — was validated in a large multi-center, blinded study enrolling over 1,000 children and adults that underpinned the U.S. clearance. The MeMed Key platform miniaturizes what had been a laboratory ELISA-style measurement into a rapid, easy-to-use device usable on serum or venous whole blood, and the company has pursued a **breakthrough-device designation** for a capillary (fingerstick) version that would push the test even closer to decentralized and austere settings. Around MeMed BV the company is extending the same host-response approach to a pipeline that includes a **MeMed Severity** product intended to flag which patients with suspected infection are likely to deteriorate — a triage and sepsis-risk use case.

**Market, customers, and go-to-market.** The commercial target is large and structural: emergency departments, urgent care, pediatrics, and primary care worldwide face the bacterial/viral dilemma millions of times a day, and health systems and governments are under mounting pressure to improve antibiotic stewardship as AMR climbs. MeMed sells a razor-and-blade model — the MeMed Key analyzer as placed instrument plus recurring single-use MeMed BV cartridges — which is the economic structure diagnostics investors prize because it converts instrument placements into consumable annuity revenue. Go-to-market combines direct commercial teams in the U.S. and Europe with **distribution leverage through Beckman Coulter (a Danaher company)**, whose immunoassay sales channel lists and markets MeMed BV, materially extending reach into hospital laboratories. Adoption in diagnostics is nonetheless reference- and evidence-driven: it depends on clinical-guideline inclusion, reimbursement coding, and peer-reviewed utility studies (such as randomized trials measuring reduced antibiotic prescribing and return visits), all of which take time.

**Traction, funding, and third-party validation.** MeMed's strongest external validation is regulatory and governmental rather than merely venture hype. On **September 20, 2021** the U.S. FDA granted 510(k) clearance to MeMed BV on the MeMed Key platform — described as the first technology cleared to distinguish bacterial from viral infection using the body's immune response — for both children and adults. On the capital side, MeMed raised a **$93 million Series E in 2021**, bringing total funding to **more than $200 million**, from a syndicate that included Horizons Ventures, Shavit Capital, Social Capital, La Maison Partners, Touchwood Capital, Caesarea Medical Holdings, Union Tech Ventures, Clal Insurance, the Phoenix, Poalim Equity, and Western Technology Investment. Critically, non-dilutive government agencies co-funded the technology: the U.S. **Defense Threat Reduction Agency (DTRA)** awarded a contract of up to **$9.2 million** to complete the point-of-care platform, the Department of Defense's Congressionally Directed Medical Research Programs supported peer-reviewed development, **BARDA's DRIVe** unit contracted MeMed to demonstrate MeMed BV's clinical utility, and the EU Commission provided further support. That constellation of FDA clearance, a major-distributor partnership, and multiple U.S. defense and biomedical-preparedness agencies underwriting the work is diligence that few private diagnostics companies can match.

**Founders and team background.** MeMed was founded in **June 2009** by **Dr. Kfir Oved** (CTO), a physician-scientist immunologist, and **Dr. Eran Eden** (CEO), a computational biologist — a pairing that maps precisely onto the company's thesis of molecular immunology fused with machine learning. The company is headquartered in **Tirat Carmel** in the Haifa area of northern Israel, with a U.S. office in **Andover, Massachusetts**, and around the time of its Series E reported roughly **100 employees** across Israel, Europe, and the U.S. (current headcount is not precisely confirmable and is likely larger). The founders' long tenure — building one platform through fifteen-plus years, a full FDA clearance, and repeated U.S. government contracting — is an execution signal in a field where many host-response ideas never clear regulators or reach commercialization.

**Competitive dynamics.** MeMed competes on several fronts. (1) Against **traditional biomarkers** — CRP and procalcitonin (Roche, bioMérieux, Abbott and others) — MeMed argues superior discrimination from its multi-protein, algorithmic approach. (2) Against **syndromic molecular panels** such as bioMérieux/BioFire FilmArray, it counters that detecting an organism is not the same as proving causation, and that host-response works even when the pathogen is unknown or inaccessible. (3) Against a rising cohort of **host-response peers** it is directly contested: Inflammatix's TriVerity uses a ~29-gene mRNA signature to assess bacterial/viral status and sepsis risk (FDA-cleared), and Cytovale's IntelliSep uses microfluidic leukocyte-deformability cytometry for ED sepsis risk (FDA-cleared 2022); Lumos Diagnostics' FebriDx offers a simpler CRP/MxA host-response point-of-care read. MeMed's plausible edges are: (i) a *first-mover FDA clearance* specifically for bacterial-vs-viral differentiation; (ii) a genuinely point-of-need 15-minute workflow on placed instruments; (iii) an unusually deep base of DoD/BARDA/EU validation; and (iv) Beckman Coulter distribution. The counter-risk is that host-response diagnostics is now a crowded, well-funded category racing for the same guideline inclusion and reimbursement.

**Defense, security, and resilience dual-use relevance.** MeMed's dual-use case is unusually concrete for a medtech company, because U.S. defense agencies have already funded it. A rapid, pathogen-agnostic, point-of-care test that tells a clinician whether an infection is bacterial or viral is directly relevant to **military medical readiness and battlefield/forward triage**, where laboratory infrastructure is absent and antibiotics must be rationed; to **biodefense and CBRN response**, where distinguishing infection type quickly during an outbreak or deliberate release matters; to **pandemic preparedness**, MeMed's stated BARDA use case; and to **antimicrobial-resistance mitigation**, a recognized national-security threat. The DTRA contract, DoD CDMRP support, and BARDA/DRIVe engagement are fielded evidence, not adjacency. Calibration: the core product remains a clinical diagnostic optimized for civilian emergency and primary care, and its defense relevance is realized through medical-readiness and preparedness channels rather than a weapons or ISR function — but within the "resilience and biosecurity" axis of a dual-use thesis, MeMed is one of the more credibly defense-connected Israeli health-tech companies.

**Growth stage, trajectory, and key diligence risks.** MeMed reads as a **mature but still-scaling** deep-tech diagnostics company: founded 2009, FDA-cleared since 2021, commercial with a marquee distributor, Series E funded, and government-validated. Trajectory from here depends on converting clearance into routine clinical use. The key diligence risks are: (1) **commercial adoption and reimbursement** — diagnostics live or die on payer coding, guideline inclusion, and hospital budget cycles, all slow; (2) **capital intensity** — instrument-placement models and clinical-evidence generation consume cash, and profitability/revenue scale are not publicly disclosed; (3) **intensifying competition** from FDA-cleared host-response rivals (Inflammatix, Cytovale) and entrenched biomarker/PCR incumbents; (4) **evidence dependence** — utility must keep being demonstrated in randomized trials showing real antibiotic-sparing and outcome benefit; (5) **government-funding concentration and procurement timelines** on the dual-use side; and (6) **headcount, current funding runway, and revenue opacity** that limit independent verification. Progression would be evidenced by guideline adoption, reimbursement wins, expanded international placements, capillary-blood clearance, and conversion of the DoD/BARDA relationships into fielded medical-readiness deployments.